ONWARDS 5 [59], with attention to technology, is a trial regarding once-weekly insulin codec vs. once-daily basal insulin analogues in people who have T2DM and have not received insulin treatment before with a dosing guide app. Here, INS is linked to type 2 diabetes mellitus.